FDA warnings to the product labeling for the following contrast agents:
Gadolinium based contrast agents - The FDA has requested manufacturers of all gadolinium based contrast agents to add new warnings about exposure to gadolinium based contrast agents, which increases the risk for nephrogenic systemic fibrosis in patients with advanced kidney disease. The full text of the warning is available at: http://www.fda.gov/cder/drug/infopage/gcca/default.htm
National Center for Biotechnology Information (US), Bethesda (MD)
Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. United States Food and Drug Administration (FDA) Warnings.